Diligence memo · auto-generated · as of July 2, 2026
Protagenic Therapeutics, Inc.\new
Protagenic Therapeutics, Inc.\new looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Protagenic Therapeutics, Inc.\new operates in Biotechnology, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Protagenic Therapeutics, Inc.\new has raised $9.4M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.3M on 2011-05-31.
Most recent recorded round closed around 2019-11-05.
Valuation (modeled)modeled
Provath models Protagenic Therapeutics, Inc.\new at approximately $24M (range $731K–$132M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.13× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 6.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 55% of Biotechnology peers (4293 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.